A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
 Recruiting
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
Breast |
Dr. Ghislain Cournoyer
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
TROPION-Breast04
NCT06112379
Recruiting
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
Breast |
Dr. Ghislain Cournoyer
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
CAMBRIA-1
NCT05774951
Recruiting
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
Breast |
Dr. Ghislain Cournoyer
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
Groupe d'étude en oncologie du Québec